Doripenem: A review of its use in the treatment of bacterial infections

Drugs

Volumn 68, Issue 14, 2008, Pages 2021-2057

  Keam, Susan J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug profiles; Bacterial infections; Doripenem, general; Intra abdominal infections, treatment; Pneumonia, treatment; Skin and soft tissue infections, treatment; Urinary tract infections, treatment

Indexed keywords

AMIKACIN; AMPICILLIN; BETA LACTAMASE INHIBITOR; BIAPENEM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTOBIPROLE; CILASTATIN; CILASTATIN PLUS IMIPENEM; COTRIMOXAZOLE; DAPTOMYCIN; DORIBAX; DORIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PROBENECID; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAEROBIC BACTERIUM; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG TOLERABILITY; ENDOCARDITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GYNECOLOGIC INFECTION; HEADACHE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; KIDNEY DISEASE; LOWER RESPIRATORY TRACT INFECTION; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; OTITIS MEDIA; OUTCOME ASSESSMENT; PHLEBITIS; POSTANTIBIOTIC EFFECT; PYELONEPHRITIS; RASH; REVIEW; SEPSIS; SIDE EFFECT; SKIN INFECTION; TONSILLITIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CARBAPENEMS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; KIDNEY DISEASES; TISSUE DISTRIBUTION;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; IAIS; NEGIBACTERIA; POSIBACTERIA;

EID: 51549090583     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868140-00007     Document Type: Review

References (166)

1. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67 (7): 1027-52
2. Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 2003; 63 (20): 2157-68
3. Shimada J, Yamaguchi K, Shiba T, et al. A new carbapenem antibiotic for injection: characteristics of doripenem [in Japanese]. Jpn J Antibiot 2005 Dec; 58 (6): 489-506
4. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996 Jan; 51 (1): 99-136
5. Lowe MN, Lamb HM. Meropenem: an updated review of its use in the management of intra-abdominal infections. Drugs 2000 Sep; 60 (3): 619-46
6. Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs 2000 Mar; 59 (3): 653-80
7. Wiseman LR, Wagstaff AJ, Brogden RN, et al. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995 Jul; 50 (1): 73-101
8. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005; 65 (15): 2151-78
9. Curran M, Simpson D, Perry C. Ertapenem: a review of its use in the management of bacterial infections. Drugs 2003; 63 (17): 1855-78
10. Perry CM, Ibbotson T. Biapenem. Drugs 2002; 62 (15): 2221-34; discussion 2235
11. Goa KL, Noble S. Panipenem/betamipron. Drugs 2003; 63 (9): 913-25; discussion 926
12. Shionogi and Co Ltd, Osaka. Prescribing information. Doripenem hydrate (Finibax®) 0.25g IV solution [in Japanese]. 2005 Jul
13. Johnson & Johnson Pharmaceutical Research Development LLC, Raritan (NJ). Doribax™ [doripenem] prescribing information 2007 Oct [online]. Available from URL: http://www.doribax.com/doribax/shared/pi/doribax.pdf#zoom= 100 [Accessed 2008 Apr 14]
14. European Medicines Authority. Summary of product characteristics: Doribax [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/ doribax/doribax.htm [Accessed 2008 Aug 5]
15. Davies TA, Shang W, Bush K, et al. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008 Apr; 52 (4): 1510-2
16. Fujimura T, Kimura Y, Yoshida I, et al. In vitro antibacterial activity of doripenem, a novel parenteral carbapenem [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 57-70
17. Davies TA, Bush K, Flamm RK. Differences in Escherichia coli and Pseudomonas aeruginosa cell morphology after exposure to doripenem, imipenem, and meropenem [abstract no. A025]. 107th General Meeting of the American Society for Microbiology; 2007 May 21-25; Toronto (ON)
18. Mori M, Hikida M, Nishihara T, et al. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I [letter]. J Antimicrob Chemother 1996 May; 37 (5): 1034-6
19. Yamano Y, Kawai Y, Yutsudo T. Stability of doripenem against human renal dehydropeptidase-I [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 92-5
20. Turnidge JD, Bell JM, Fritsche TR, et al. Doripenem activity tested against Gram-negative pathogens in the Asia-Pacific (APAC) region: report from the SENTRY Antimicrobial Surveillance Program, 2006 [abstract no. E260 plus poster]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
21. Evangelista AT, Yee YC, Pillar CM, et al. Surveillance profiling of doripenem (DOR) activity against Pseudomonas aeruginosa (PA) isolated from inpatients (IP) and ICU patients (ICU); results of the TRUST surveillance initiative [abstract no. 523]. 45th Annual Infectious Diseases Society of America; 2007 Oct 4-7; San Diego (CA), 159
22. Fritsche TR, Sader HS, Strabala P, et al. Antimicrobial activities of doripenem and other carbapenems tested against Pseudomonas aeruginosa, other non-fermentative bacilli and Aeromonas spp [abstract no. E-0222 plus poster]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA), 177
23. Fritsche TR, Sader HS, Strabala P, et al. Activity of doripenem tested against an international collection of ESBL- and AmpC-producing Enterobacteriaceae [abstract no. E-0219 plus poster]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA), 176
24. Fritsche T, Sader HS, Strabala P, et al. Spectrum and activity of doripenem, an investigational carbapenem, tested against bacterial pathogens recovered from patients hospitalized with pneumonia (Europe 2004-2006) [abstract no. 2087 plus poster]. 17th European Congress of Clinical Microbiology and Infectious Diseases; 2007 Mar 31-Apr 3; Munich
25. Fritsche TR, Sader HS, Jones RN. Geographic variations in the activity of doripenem and other broad-spectrum agents: results from an international surveillance program (2003-2005) [abstract no. C2-1836 plus poster]. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
26. Fritsche TR, Jones RN. Antimicrobial activity of broad-spectrum β-lactams, including doripenem, tested against bloodstream infection isolates: a global surveillance report (2003-2005) [abstract no. 200]. 44th Annual Infectious Diseases Society of America; 2006 Oct 12-15; Toronto (ON), 81
27. Fritsche T, Sader HS, Strabala P, et al. Variations and trends in the activity of doripenem and other broad-spectrum agents against leading bacterial pathogens: results from a European surveillance program (2003-2006) [abstract no. P 2088 plus poster]. 17th European Congress of Clinical Microbiology and Infectious Diseases; 2007 Mar 31-Apr 3; Munich
28. Aranza M, Pillar C, Draghi D, et al. Baseline surveillance profile of doripenem against key Gram-negative pathogens encountered in Europe [abstract no. 1664 plus poster]. 17th European Congress of Clinical Microbiology and Infectious Diseases; 2007 Mar 31-Apr 3; Munich
29. Brown NP, Jones ME, Draghi DC, et al. Baseline surveillance profile of doripenem against key Gram-negative pathogens encountered in the United States [abstract no. E221 plus poster]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA), 177
30. Brown NP, Jones ME, Draghi DC, et al. Profile of doripenem activity against Gram-positive pathogens: results of a 2005-2006 surveillance initiative [abstract no. E220 plus poster]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA), 176-7
31. Pillar CM, Aranza MK, Shah D, et al. Analysis of doripenem activity, relative to other carbapenems, against target Gram-negative pathogens isolated from specific infection sites [abstract no. E-262 plus poster]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL), 185
32. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005 Dec; 11 (12): 974-84
33. Kaniga K, Prokimer P, Llorens L, et al. Prevalence of extended-spectrum beta-lactamase (ESBL) and fluoroquinolone-resistant isolates from phase 3 trials of nosocomial pneumonia and their susceptibility to doripenem (DOR) [abstract no. E265]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
34. Queenan AM, Shang W, Amsler K, et al. Characterization of ESBLs from Enterobacteriaceae collected during doripenem clinical trials [abstract no. C2-1519]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
35. Kaniga K, Umeh O, Llorens L, et al. Activity of doripenem against isolates from phase 3 trials of complicated intra-abdominal infections [abstract no. E-264 plus poster]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
36. Kaniga K, Redman R, Llorens L, et al. Prevalence of extended-spectrum beta-lactamase producers (ESBLs) and fluoroquinolone-resistant isolates from phase 3 trials of complicated urinary tract infections (UTIs) including pyelonephritis [abstract no. E-925 plus poster]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
37. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob Agents Chemother 2008 Feb; 52 (2): 761-6
38. Aranza MK, Pillar CM, Shah D, et al. Stratified analysis of doripenem activity against Enterobacteriaceae and Pseudomonas aeruginosa according to patient location: inpatients and ICU patients [abstract no. E-263 plus poster]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
39. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J Antimicrob Chemother 2005 Jun; 55 (6): 944-9
40. Fritsche TR, Johnson D, Jones RN. Antimicrobial activity of doripenem against multi-drug resistant Pseudomonas aeruginosa and Streptococcus pneumoniae [abstract no. E2014]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington DC, 175
41. Ge Y, Wikler MA, Sahm DF, et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004 Apr; 48 (4): 1384-96
42. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007 Aug; 51 (8): 2716-9
43. Credito KL, Ednie LM, Appelbaum PC. Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. Antimicrob Agents Chemother 2008 Jan; 52 (1): 365-73
44. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004 Aug; 48 (8): 3136-40
45. Jones RN, Huynh HK, Biedenbach DJ, et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004 Jul; 54 (1): 144-54
46. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004 Aug; 48 (8): 3086-92
47. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004 Apr; 48 (4): 1313-9
48. Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother 2006 Feb; 50 (2): 819-21
49. Wexler HM, Engel AE, Glass D, et al. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 2005 Oct; 49 (10): 4413-7
50. Davies TA, Shang W, Bush K, et al. Activity of doripenem and comparator β-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x [letter]. J Antimicrob Chemother 2008 Mar; 61 (3): 751-3
51. Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005 May; 52 (1): 71-4
52. Yamano Y, Nishikawa T, Fujimura T, et al. Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem. J Antibiot (Tokyo) 2006 Dec; 59 (12): 791-6
53. Nomura S, Nagayama A. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections. J Chemother 2002 Apr; 14 (2): 155-60
54. Mikamo H, Izumi K, Hua YX, et al. In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. J Antimicrob Chemother 2000 Sep; 46 (3): 471-4
55. Watanabe A, Takahashi H, Kikuchi T, et al. Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens. Chemotherapy 2000 May 30; 46 (3): 184-7
56. Shimauchi C, Kaneko K, Sato Y, et al. Comparative basic study of carbapenems antibiotics against Pseudomonas aeruginosa [in Japanese]. Jpn J Chemother 2005; 53 (12): 732-40
57. Kuwahara-Arai K, Hiramatsu K. In vitro activity of doripenem against Gram-positive and Gram-negative bacteria isolates [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 17-23
58. Miwa H, Kimura Y, Jinushi Y, et al. Antipseudomonal activity of doripenem, a novel parenteral carbapenem antibiotic [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 80-91
59. Okamoto R, Nakano R, Sato Y, et al. Antibacterial activity of doripenem against β-lactamase-producing strains [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 47-51
60. Tanaka K, Watanabe K. In vitro activity of doripenem, a 1β-methylcarbapenem, against anaerobic bacteria [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 24-31
61. Yoshida I, Sugimori G, Higashiyama I, et al. Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial agents: antimicrobial activity against Gram-negative bacteria isolated in 2000 [in Japanese]. Jpn J Chemother 2003; 51 (4): 209-32
62. Masuda N, Sakagawa E, Ohya S, et al. Hypersusceptibility of the Pseudomonas aeruginosa nfxB mutant to β-lactams due to reduced expression of the AmpC β-lactamase. Antimicrob Agents Chemother 2001 Apr; 45 (4): 1284-6
63. Tsuji M, Furuya N, Matsumoto T, et al. In vitro and in vivo antibacterial activity of DRPM, a new carbapenem [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 1-16
64. Mikamo H, Tamaya T. Antimicrobial susceptibility and pharmacokinetics of doripenem in the field of obstetrics and gynecology [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 286-92
65. Sugihara K, Tateda K, Shibuya R, et al. In vitro activity of CS-023 (RO4908463) against recent clinical isolates of Gram-positive and -negative pathogens in Japan [abstract no. E271]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
66. Kobayashi Y, Sumitani Y, Sugita K, et al. Antimicrobial activity of meropenem against main bacterial species isolated from patient blood in 2006 [in Japanese]. Jpn J Antibiot 2007 Dec; 60 (6): 378-86
67. Chen Y, Garber E, Zhao Q, et al. In vitro activity of doripenem (S-4661) against multidrug-resistant Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005 Jun; 49 (6): 2510-1
68. Jones RN, Sader HS, Fritsche TR, et al. Selection of a surrogate β-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem. Diagn Microbiol Infect Dis 2007 Dec; 59 (4): 467-72
69. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. M100-S18 Vol.28 No 1. Wayne (PA): Clinical and Laboratory Standards Institute, 2008 Jan
70. Nishino T, Otsuki M, Izawa M. In vitro and in vivo antibacterial activity of doripenem [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 32-46
71. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard - seventh edition. M11-A7 Vol 27 No. 2. Wayne (PA): Clinical and Laboratory Standards Institute, 2008 Jan
72. Mushtaq S, Warner M, Ge Y, et al. In vitro interactions of doripenem with other antibacterials [abstract no. E-307]. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington, DC
73. Foleno B, Wira E, Bush K, et al. Ceftobiprole in-vitro interactions with doripenem, levofloxacin, or colistin against Pseudomonas aeruginosa, Acinetobacter baumannii, and fluoroquinolone-resistant Escherichia coli [abstract no. 286]. 44th Annual Infectious Diseases Society of America; 2006 Oct 12-15; Toronto (ON), 99
74. Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother 2005 Oct; 11 (5): 259-61
75. Ishii Y, Sugihara S, Tateda K, et al. In vitro synergistic effects of combinations of CP3242, as a novel metallo-β-lactamase inhibitor, and carbapenems against carbapenemase producing organisms [abstract no. F1-331]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
76. Mushtaq S, Warner M, Kaniga K, et al. Bactericidal activity of doripenem vs. Pseudomonas aeruginosa [abstract no. F-1162 plus oral presentation]. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington, DC, 187
77. Totsuka K, Kikuchi K. In vitro postantibiotic effect and in vivo antimicrobial activity of doripenem, a new carbapenem [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 52-6
78. Nishio H, Komatsu M, Shibata N, et al. Metallo-β-lactamase-producing Gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. J Clin Microbiol 2004 Nov; 42 (11): 5256-63
79. Deshpande LM, Jones RN, Fritsche TR, et al. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist 2006; 12 (4): 223-30
80. Okamoto K, Gotoh N, Nishino T. Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. J Infect Chemother 2002 Dec; 8 (4): 371-3
81. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004; 64 (2): 159-204
82. Mesaros N, Nordmann P, Plésiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007 Jan; 13: 560-78
83. Pumbwe L, Ueda O, Yoshimura F, et al. Bacteroides fragilis BmeABC efflux systems additively confer intrinsic antimicrobial resistance. J Antimicrob Chemother 2006; 58 (1): 37-46
84. Pumbwe L, Glass D, Wexler HM. Efflux pump overexpression in multiple-antibiotic-resistant mutants of Bacteroides fragilis. Antimicrob Agents Chemother 2006 Sep; 50 (9): 3150-3
85. Sakyo S, Tomita H, Tanimoto K, et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot (Tokyo) 2006 Apr; 59 (4): 220-8
86. Kim SY, Park YJ, Yu JK, et al. Prevalence and mechanisms of decreased susceptibility to carbapenems in Klebsiella pneumoniae isolates. Diagn Microbiol Infect Dis 2007 Jan; 57 (1): 85-91
87. Morrow BJ, Andrew T, Queenan A, et al. P. aeruginosa DNA microarray analysis reveals differential induction of ampC and efflux by imipenem and doripenem [abstract no. C1-0037 plus poster]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA), 66
88. Queenan AM, Shang W, Flamm RK, et al. Effect of doripenem on AmpC induction in Enterobacteriaceae and Pseudomonas aeruginosa [abstract no. C1-0040 plus poster]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA), 66-7
89. Ramsey DM, Wozniak DJ. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol Microbiol 2005 Apr; 56 (2): 309-22
90. Bagge N, Schuster M, Hentzer M, et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and β-lactamase and alginate production. Antimicrob Agents Chemother 2004 Apr; 48 (4): 1175-87
91. Andrew T, Morrow B, Bush K, et al. Pseudomonas aeruginosa DNA microarray analysis reveals differential induction of alginate and repression of flagellar gene expression by imipenem and doripenem [abstract no. A097 plus poster]. 107th General Meeting of the American Society for Microbiology; 2007 May 21-25; Toronto (ON)
92. Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis 2006 Jul; 55 (3): 241-3
93. Hilliard JJ, Melton J, Zhang W, et al. In vivo activity of doripenem against systemic E. coli infections in the mouse [abstract no. 435]. 45th Annual Infectious Diseases Society of America; 2007 Oct 4-7; San Diego (CA), 139
94. Hilliard JJ, Melton J, Zhang W. In vivo activity of doripenem, imipenem, meropenem, and ceftazidime against systemic pseudomonal infections in the mouse [abstract no. 434]. 45th Annual Infectious Diseases Society of America; 2007 Oct 4-7; San Diego (CA), 139
95. Sato T, Tsuji M, Okazaki K, et al. Therapeutic efficacy of doripenem, a novel parenteral carbapenem antibiotic, against experimental infection in mice and rats [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 71-9
96. Katsube T, Yamano Y, Yano Y. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. J Pharm Sci 2008 Apr; 97 (4): 1606-14
97. Hilliard J, Melton J, Zhang W, et al. In vivo anti-pseudomonal activity of doripenem [abstract no. 199]. 44th Annual Infectious Diseases Society of America; 2006 Oct 12-15; Toronto (ON), 81
98. Fernandez J, Zhang W, . In vivo activity of doripenem in a pseudomonal murine skin infection model [abstract no. 196]. 44th Annual Infectious Diseases Society of America; 2006 Oct 12-15; Toronto (ON)
99. Horiuchi M, Kimura M, Tokumura M, et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 2006 May 1; 222 (1-2): 114-24
100. Floren L, Wikler M, Kilfoil T, et al. A phase 1 open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics of doripenem administered intravenously to subjects with renal impairment [abstract no. A-17 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington DC, 4
101. Nakashima M, Sesoko S, Oguma T. Phase I study of doripenem, a new carbapenem antibiotic for injection, in elderly volunteers [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 124-9
102. Nakashima M, Oguma T. Phase I study of doripenem, a new carbapenem antibiotic for injection in healthy volunteers [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 104-23
103. Shiba K, Nakashima M. Effect of probenecid on pharmacokinetics of doripenem in healthy male volunteers [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 136-42
104. Uehara S, Murao W, Seno Y, et al. Pharmacokinetics of doripenem in patients with renal dysfunction [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 130-5
105. Thye DA, Kilfoil T, Leighton A, et al. Doripenem: a phase 1 study to evaluate safety, tolerability and pharmacokinetics in a Western healthy volunteer population [abstract no. A-21 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14 -17; Chicago (IL)
106. Ikawa K, Morikawa N, Urakawa N, et al. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother 2007 Dec 1; 60 (6): 1395-7
107. Tanimura H, Aikawa N, Sumiyama Y, et al. Pharmacokinetic profiles and clinical efficacy of doripenem in surgical infection [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 260-72
108. Okada H, Yasuda J, Hirabayashi K, et al. Basic and clinical studies on doripenem in obstetrics and gynecology [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 273-85
109. Baba S, Suzuki K, Miyamoto N. A study of distribution of doripenem in otolaryngologic tissues and clinical relevance in otolaryngologic infection [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 293-302
110. Sasaki J, Kaneko A. Clinical studies on doripenem of dentistry and oral surgery [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 323-31
111. Ooishi M, Miyanaga Y, Ohno S, et al. Study of doripenem distribution in ocular tissue and its clinical relevance in ophthalmological infection [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 313-22
112. Arata J, Watanabe S, Miyachi Y, et al. Laboratory and clinical evaluation of doripenem in deep-seated skin infection [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 303-12
113. Nakajima Y, Mizobuchi M, Nakamura M, et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 2004 Dec; 32 (12): 1383-91
114. Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev 2007; 39 (4): 647-57
115. Van Wart S, Bhavnani SM, Phillips L, et al. Population pharmacokinetics of doripenem [abstract no. A-18 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington DC, 4
116. Johnson & Johnson Pharmaceutical Research and Development LLC Raritan (NJ). Doribax (doripenem) injection new drug application 22-106. Clinical pharmacology and biopharmaceutics review(s) 2007 Oct 12 [online]. Available from URL: http://www.fda.gov.cder/foi/nda/2007/022106TOC.htm [Accessed 2008 May 19]
117. Hori T, Nakano M, Kimura Y, et al. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo 2006 Jan-Feb; 20 (1): 91-6
118. Mouton JW, Touw DJ, Horrevorts AM, et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000 Sep; 39: 185-201
119. Bhavnani SM, Hammel JP, Cirincione BB, et al. Use of pharmacokinetic- pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005 Sep; 49 (9): 3944-7
120. Andes DR, Kiem S, Craig WA. In vivo pharmacodynamic activity of a new carbapenem, doripenem (DOR), against multiple bacteria in a murine thigh infection model [abstract no. A-308]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago (IL), 10
121. Andes DR, Craig WA, Bhavnani SM, et al. PK-PD evaluation of doripenem (DOR) against extended spectrum β-lactamase (ESBL) producing Enterobacteriaceae [abstract no. 182]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 Oct 9-12; San Diego (CA), 59
122. Ambrose PG, Phillips L, Bhavnani SM, et al. Use of pharmacokinetics- pharmacodynamics (PK-PD) as decision support for phase 3 dose justification for doripenem [abstract no. A-140]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington DC, 12
123. Kuroda N, Munekage T, Yamano Y. Bactericidal activity of doripenem using in vitro pharmacodynamic models [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 96-103
124. Kim A, Banevicius MA, Nicolau DP. In vivo pharmacodynamic profiling of doripenem human simulated exposures against Pseudomonas aeruginosa. Antimicrob Agents Chemother. Epub 2008 May 5
125. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 (published erratum appears in Crit Care Med 2008 Apr; 36 (4): 1394-6). Crit Care Med 2008 Jan; 36 (1): 296-327
126. Réa-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008 Jun 11; 24 (7): 2113-26
127. Saito A, Watanabe A, Nakata K, et al. Comparative study of doripenem and meropenem in respiratory infections. Phase III double-blind comparative study [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 185-204
128. Saito A, Watanabe A, Odagiri S, et al. A dose-finding study on doripenem in chronic respiratory tract infection [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 169-84
129. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008 Apr; 36 (4): 1089-96
130. Kollef MH, Rello J, Prokocimer P, et al. Efficacy of doripenem in nosocomial pneumonia: non-ventilator-associated and ventilator-associated pneumonia [abstract]. Chest 2007 Oct; 132 (4 Suppl.): 498-9s
131. Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008 May; 30 (5): 868-83
132. Malafaia O, Umeh O, Jiang J. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections [abstract no. L-1564b plus poster]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
133. Solomkin JS, Umeh O, Jiang J, et al. Doripenem vs. meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections [abstract no. L-487 plus poster]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
134. Naber K, Redman R, Kotey P, et al. Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis [abstract no. 833 plus poster]. 17th European Congress of Clinical Microbiology and Infectious Diseases and the 25th International Congress of Chemotherapy; 2007 Mar 31-Apr 3; Munich
135. Kamidono S, Arakawa S, Hirose T, et al. Double-blind, controlled study to evaluate safety and efficacy of doripenem and meropenem in patients with complicated urinary tract infection [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 244-59
136. Saito A, Shimada J, Shiba K, et al. A study of doripenem efficacy and safety in internal medicine [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 157-68
137. Shimada J, Yamaguchi K, Shiba K, et al. Early phase II study of doripenem, a new carbapenem antibiotic for injection [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 143-56
138. Kamidono S, Arakawa S, Kumon H, et al. A dose-finding study of doripenem in patients with complicated urinary tract infection [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 230-43
139. Kamidono S. Late phase II study of doripenem in urological infections [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 216-29
140. Saito A, Kamidono S, Yokoyama T, et al. Study of safety and efficacy of doripenem in patients with sepsis and infective endocarditis [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 332-40
141. Saito A, Watanabe A, Itabashi S, et al. Therapeutic exploratory study of the efficacy and safety of doripenem in patients with hospital-acquired pneumonia [in Japanese]. Jpn J Chemother 2005; 53 Suppl. 1: 205-15
142. Merchant S, Gast C, Nathwani D, et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008 Apr; 30 (4): 717-33
143. Psathas PA, Kuzmission A, Ikeda K, et al. Stability of doripenem for
144. Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother 2008 Mar; 9 (4): 561-75
145. Helfand MS, Bonomo RA. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum β-lactamases and metallo-β-lactamases on the treatment of resistant Gram-negative pathogens. Curr Opin Pharmacol 2005 Oct; 5 (5): 452-8
146. Kollef MH. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respir Care 2004 Dec; 49 (12): 1530-41
147. Johnson & Johnson Pharmaceutical Research and Development LLC, Raritan (NJ). FDA extends review timeline for additional indication for antibiotic DORIBAX™ 2008 Mar 6 [media release]. Available from URL: http://www.jnj.com/news [Accessed 2008 Apr 7]
148. AstraZeneca Pharmaceuticals LP, Wilmington (DE). Merrem® I.V. (meropenem for injection). US prescribing information [online]. Available from URL: http://www.astrazenecaus.com/pi/MerremIV.pdf [Accessed 2008 May 20]
149. Merck and Co Inc., Whitehouse Station (NJ). Primaxin® I.V. (imipenem and cilastin for injection). US prescribing information 2007 Dec [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/p/primaxin/ primaxin_iv_pi.pdf [Accessed 2008 May 20]
150. Baldwin CM, Lyseng-Williamson K, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008; 68 (6): 803-41
151. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005 Nov 15; 41 (10): 1373-406
152. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003 Oct 15; 37 (8): 997-1005
153. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. ERS Task Force in collaboration with ESCMID. Eur Respir J 2005 Dec; 26 (6): 1138-80
154. Wilkinson M, Woodhead MA. Guidelines for community-acquired pneumonia in the ICU. Curr Opin Crit Care 2004 Feb; 10 (1): 59-64
155. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Thoracic Society. Am J Respir Crit Care Med 2005 Feb 15; 171 (4): 388-416
156. Naber KG, Bishop MC, Bjerklund-Johansen TE, et al. Guidelines on the management of urinary and male genital tract infections. European Association of Urology [online]. Available from URL: http://www.uroweb.org/fileadmin/ user_upload/Guidelines/15%20Male%20UTI.pdf [Accessed 2008 Mar 11]
157. Gilbert DN, Moellering RC, Eliopoulos GM, et al, editors. Sanford guide to antimicrobial therapy 2008. 38th ed. Sperryville (VA): Antimicrobial Therapy Inc, 2008 Apr 15
158. Tanaka A, Takada T, Kawarada Y, et al. Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14 (1): 59-67
159. Miyashita N, Matsushima T, Oka M. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med 2006; 45 (7): 419-28
160. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005 Jun; 55 (6): 965-73
161. Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006 Sep 1; 43 Suppl. 2: S100-5
162. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007; 67 (3): 351-68
163. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008 Mar 20; 358 (12): 1271-81
164. Gilad J, Carmeli Y. Treatment options for multidrug-resistant Acinetobacter species. Drugs 2008; 68 (2): 165-89
165. Giamarellou H, Kanellakopoulou K. Current therapies for Pseudomonas aeruginosa. Crit Care Clin 2008 Apr; 24 (2): 261-78
166. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 2004; 50 Suppl. 1: 3-10